Author/Authors :
Saki، Najmaldin نويسنده Department of Hematology and Blood Banking School of Medical Sciences, Tarbiat Modares University, Tehran, Iran , , Abroun، Saeid نويسنده Hematology Department, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran , , Soleimani، Masoud نويسنده , , Kavianpour، Maria نويسنده Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran , , Shahjahani، Mohammad نويسنده Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran , , Mohammadi Asl، Javad نويسنده , , Hajizamani، Saeideh نويسنده Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ,
Abstract :
Today the regulatory role of microRNAs (miRs) is well characterized in many diverse cellular
processes. MiR-based regulation is categorized under epigenetic regulatory mechanisms.
These small non-coding RNAs participate in producing and maturing erythrocytes,
expressing hematopoietic factors and regulating expression of globin genes by post-transcriptional
gene silencing. The changes in expression of miRs (miR-144/-320/-451/-503)
in thalassemic/sickle cells compared with normal erythrocytes may cause clinical severity.
According to the suppressive effects of certain miRs (miR-15a/-16-1/-23a/-26b/-27a/-451)
on a number of transcription factors [myeloblastosis oncogene (MYB), B-cell lymphoma
11A (BCL11A), GATA1, Krüppel-like factor 3 (KLF3) and specificity protein 1 (Sp1)] during
B globin gene expression, It has been possible to increasing ? globin gene expression
and fetal hemoglobin (HbF) production. Therefore, this strategy can be used as a novel
therapy in infusing HbF and improving clinical complications of patients with hemoglobinopathies.
